Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
24,016,363
-
Share change
-
-712,728
-
Total reported value
-
$204,376,632
-
Price per share
-
$8.51
-
Number of holders
-
55
-
Value change
-
-$6,281,199
-
Number of buys
-
30
-
Number of sells
-
21
Institutional Holders of ALPINE IMMUNE SCIENCES INC - COM (ALPN) as of Q2 2022
As of 30 Jun 2022,
ALPINE IMMUNE SCIENCES INC - COM (ALPN) was held by
55 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
24,016,363 shares.
The largest 10 holders included
Decheng Capital Management III (Cayman), LLC, ORBIMED ADVISORS LLC, Frazier Life Sciences Management, L.P., Omega Fund Management, LLC, Lynx1 Capital Management LP, BVF INC/IL, Avidity Partners Management LP, BlackRock Inc., Paradigm Biocapital Advisors LP, and VANGUARD GROUP INC.
This page lists
55
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.